Background: Romosozumab is a bone-forming antibody that increases bone formation and
decreases bone resorption. We conducted a double-blinded, randomized, phase-2, dose …

Background: Romosozumab is an antibody that binds and inhibits sclerostin, thereby
increasing bone formation and decreasing bone resorption. A double-blinded, randomized …

Introduction: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the
canonical Wnt signaling bone formation pathway. Romosozumab is a humanized …

The study was conducted to illustrate the effect of Romosozumab in postmenopausal
osteoporosis patients. Romosozumab decreased the incidence of vertebral, nonvertebral …

This study aimed to determine the interaction between baseline FRAX® fracture probability
and romosozumab efficacy. Using an ITT approach, it was determined that the efficacy of …

Increased understanding of bone biology has led to the discovery of several unique
signaling pathways that regulate bone formation and resorption. The Wnt signaling pathway …

Aim: To conduct a systematic review and meta-analysis of randomized controlled trials
(RCTs) to evaluate the safety and efficacy of romosozumab in the treatment of …

Osteoporosis is a systemic bone disease characterized by low bone mass,
microarchitectural deterioration, increased bone fragility, and fracture susceptibility. It …

Romosozumab was approved in April 2019 for the treatment of postmenopausal women
with osteoporosis at high risk for fracture. It is a monoclonal antibody, which binds and …

Romosozumab is an effective treatment for spine osteoporosis because it reduces the
incidence of new fractures and significantly increases the percent change in the spine BMD …